Spots Global Cancer Trial Database for Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
Official Title: Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for Hepatocellular Carcinoma (HCC)
Study ID: NCT04459468
Conditions
Interventions
Study Description
Brief Summary: This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment and obtain blood samples pre and post TACE for biomarker identification using bead based X-aptamer library. No intervention is planned.
Detailed Description: This is a prospective, non-blinded, multi-arm study. Patients at 18 - 70 years old with liver cancer will be enrolled. The approach is to identify novel proteomic biomarkers for HCC patients treated with Lipiodol TACE using beads-based X-aptamer library, then validate and create a biomarker panel that can be used to predict the outcome of HCC post-Lipiodol TACE treatment. Lipiodol TACE will be done as standard of care and the only thing done as research will be blood draws pre and post-TACE.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UT Southwestern Medical Center, Dallas, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
